KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)R&D In Process
Ratios

CRISPR Therapeutics AG (CRSP) Leases (2019 - 2025)

CRISPR Therapeutics AG's Leases history spans 7 years, with the latest figure at $131.7 million for Q4 2025.

  • For Q4 2025, Leases fell 8.18% year-over-year to $131.7 million; the TTM value through Dec 2025 reached $131.7 million, down 8.18%, while the annual FY2025 figure was $131.7 million, 8.18% down from the prior year.
  • Leases for Q4 2025 was $131.7 million at CRISPR Therapeutics AG, down from $134.7 million in the prior quarter.
  • Across five years, Leases topped out at $179.4 million in Q2 2021 and bottomed at $50.1 million in Q1 2021.
  • The 5-year median for Leases is $153.7 million (2023), against an average of $149.6 million.
  • The largest annual shift saw Leases surged 356.48% in 2021 before it fell 10.61% in 2023.
  • A 5-year view of Leases shows it stood at $174.5 million in 2021, then fell by 10.05% to $156.9 million in 2022, then fell by 1.87% to $154.0 million in 2023, then decreased by 6.84% to $143.5 million in 2024, then decreased by 8.18% to $131.7 million in 2025.
  • Per Business Quant, the three most recent readings for CRSP's Leases are $131.7 million (Q4 2025), $134.7 million (Q3 2025), and $137.6 million (Q2 2025).